MedTrace Logo

Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)

NCT06781255 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2026-04-06

No results posted yet for this study

Summary

A non-randomized study evaluating the safety of an orally administered inflammasome inhibitor, K9, for the treatment of diabetic macular edema (DME).

Conditions

Interventions

DRUG

Kamuvudine-9

96 mg tablets taken twice a day for 24 weeks

Sponsors & Collaborators

  • Inflammasome Therapeutics

    collaborator INDUSTRY

  • Michelle Abou-Jaoude

    lead OTHER

Principal Investigators

  • Michelle Abou-Jaoude, MD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2026-02-25
Completion
2026-02-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06781255 on ClinicalTrials.gov